A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2029

Conditions

Acute Myeloid LeukemiaMyelodysplastic SyndromesMyeloid MalignanciesMDSInherited Bone Marrow Failure SyndromeMyeloid NeoplasmAml

Interventions

DRUG

Decitabine

Nucleoside metabolic inhibitor, via IV infusion.

DRUG

Filgrastim

Recombinant granulocyte colony-stimulating factor (G-CSF), via subcutaneous injection.

Trial Locations (2)

RECRUITING

Boston Children's Hospital, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

Harvard Clinical and Translational Science Center (Harvard Catalyst)

UNKNOWN

lead

Franziska Wachter

OTHER